Citigroup
GLUE icon

Citigroup’s Monte Rosa Therapeutics GLUE Stock Holding History

Citigroup’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240K Buy
14,575
+3,889
+36% +$74.4K ﹤0.01% 3927
2025
Q4 		$168K Buy
10,686
+8,912
+502% +$120K ﹤0.01% 4075
2025
Q3 		$13.1K Sell
1,774
-21,139
-92% -$112K ﹤0.01% 4943
2025
Q2 		$103K Sell
22,913
-8,201
-26% -$36.6K ﹤0.01% 4387
2025
Q1 		$144K Sell
31,114
-13,769
-31% -$84.4K ﹤0.01% 4382
2024
Q4 		$311K Buy
44,883
+14,780
+49% +$111K ﹤0.01% 4130
2024
Q3 		$160K Buy
30,103
+20,565
+216% +$104K ﹤0.01% 4501
2024
Q2 		$35.7K Buy
9,538
+3,640
+62% +$18.6K ﹤0.01% 4777
2024
Q1 		$41.6K Buy
5,898
+1,500
+34% +$8.9K ﹤0.01% 4710
2023
Q4 		$24.8K Buy
4,398
+3,691
+522% +$14.5K ﹤0.01% 4896
2023
Q3 		$3.39K Sell
707
-10,271
-94% -$66.1K ﹤0.01% 4824
2023
Q2 		$75.2K Buy
10,978
+9,939
+957% +$64.3K ﹤0.01% 4380
2023
Q1 		$8.09K Sell
1,039
-301
-22% -$2.09K ﹤0.01% 4818
2022
Q4 		$10.2K Sell
1,340
-170
-11% -$1.42K ﹤0.01% 4833
2022
Q3 		$12K Sell
1,510
-1,675
-53% -$15.4K ﹤0.01% 4925
2022
Q2 		$31K Buy
3,185
+690
+28% +$6.93K ﹤0.01% 4775
2022
Q1 		$35K Sell
2,495
-2,308
-48% -$32K ﹤0.01% 4889
2021
Q4 		$98K Buy
4,803
+3,482
+264% +$72.9K ﹤0.01% 4743
2021
Q3 		$29K Buy
+1,321
New +$37.9K ﹤0.01% 5048

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citigroup's GLUE Position: Q1 2026 in Review

Citigroup increased its Monte Rosa Therapeutics (GLUE) stake by 36% in Q1 2026, buying an estimated $74.4K and bringing the position to 14,575 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #3927.

Citigroup first reported a position in GLUE in Q3 2021 and has held it in 19 quarters since. The position peaked at $311K in Q4 2024. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Citigroup held 14,575 shares of Monte Rosa Therapeutics worth $240K as of Q1 2026.
  • Citigroup bought 3,889 Monte Rosa Therapeutics shares in Q1 2026, an estimated $74.4K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3927 holding.
  • Citigroup first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Citigroup's Monte Rosa Therapeutics position peaked at $311K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.